← boardnext 2027-03
ALGS
Aligos Therapeuticsdistress 3/10 · well-funded / low risk$5.09-1%today-62% from 52w high
Infectious Disease 5
Lead: chronic hepatitis B virus (HBV) infection · target HBV · est. market ~$10B (approx, global)
Revenue
pre-revenue
Liquidity
$55M
Runway
0.7 yrs
Shares 1y
+12%
Price & events
-40.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.2%
1D
-11.5%
1W
-9.9%
1M
-17.0%
3M
-37.3%
6M
-45.2%
1Y
-63.0%
2Y
-98.8%
5Y
-99.2%
All
Overview
- Market Cap
- $216.88M
- Volume
- 14.17K
- 52 Week Range
- $4.91 – $13.29
- Total Shares
- 42.61M
- Float Shares
- 3.65M
- Short %
- 10.35%
- % Held by Insiders
- 10.76%
- % Held by Institutions
- 55.08%
- RVOL
- 0.07x
- Beta
- 2.26
Pipeline stages · 3 programs
ALG-000184, TDF
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pevifoscorvir Sodium (ALG-000184)HBV
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Carbamazepine, Itraconazole (Sporanox), ALG-000184HBV
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 8 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03 Estimated 50% readout ~2027-04-15 | Phase 2 | ALG-000184, TDF | Chronic Hepatitis B Infection | — | recruiting |
| 2026-06-15 | Phase 1 | Pevifoscorvir Sodium (ALG-000184)fast track | Chronic Hepatitis B Infection | 30 | recruiting |
| 2026-04-20 | Phase 1 | Pevifoscorvir Sodium (ALG-000184)fast track | Chronic Hepaititis B Infections | 16 | recruiting |
| 2025-07-23 | Phase 1 | ALG-097558 | COVID 19 | 12 | completed |
| 2025-07-16 | Phase 1 | ALG-097558 | COVID-19 | 16 | completed |
Show all 8 trials · 3 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-07-07 | Phase 1 | Carbamazepine, Itraconazole (Sporanox), ALG-000184 | Healthy Volunteer | 24 | active not recruiting |
| 2025-06-16 | Phase 1 | ALG-000184, Entecavir | Chronic Hepatitis B | 165 | completed |
| 2025-05-08 | Phase 1 | ALG-055009 | Healthy Volunteer Study | 8 | completed |
Catalyst news & presentations · 5
- 2027Guided 40%readoutPhase 2pevifoscorvir sodium · Topline data expected.SEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- second half of 2026enrollment completesecondaryPhase 2pevifoscorvir sodium · Completion of enrollment in the HBeAg- cohort expected.SEC 8-K
- second half of 2026readoutPhase 2pevifoscorvir sodium · Second interim analysis expected.SEC 8-K
- 2026-04-16partnershipPevifoscorvir Sodium · Exclusive license deal with Xiamen Amoytop Biotech to develop and commercialize in Greater China.PR wire
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $56 (+1006% upside) · 7 analysts
- 2026-05-28Lake StreetBuy
- 2026-05-21Cantor FitzgeraldOverweight
- 2026-03-26WestPark CapitalBuy
- 2026-03-11HC Wainwright & Co.Buy
- 2026-01-07UBSBuy
- 2025-09-12HC Wainwright & Co.Buy
Competitors — HBV
- VIRVir Biotechnology, Inc.$1.6B · D4
Recent news
- 2026-07-23ALGS Q2'26 Earnings: revenue estimate is 24.68M USD - TradingView
- 2026-07-21PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis - GlobeNewswire
- 2026-07-21PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis - GlobeNewswire
- 2026-07-14H.C. Wainwright reiterates Aligos stock rating on trial enrollment By Investing.com - Investing.com South Africa
- 2026-07-14H.C. Wainwright reiterates Aligos stock rating on trial enrollment - Investing.com UK
- 2026-07-14H.C. Wainwright reiterates Aligos stock rating on trial enrollment By Investing.com - Investing.com India
- 2026-07-14H.C. Wainwright reiterates Aligos stock rating on trial enrollment By Investing.com - Investing.com Australia
- 2026-07-14H.C. Wainwright reiterates Aligos stock rating on trial enrollment By Investing.com - Investing.com Australia
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.